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Although the incidence of fulminant hepatic failure 
appears to have decreased worldwide, the management 
of this dreaded condition remains unsatisfactory (1). 
Despite ingenious methods of treatment, the mortality in 
patients with grade IV coma is still between 80 and 90% 
in most major series (15, 20). Furthermore the mortality 
is nearly 100% in patients ov~r the age of 45 who de-
velop grade IV coma (7). 
Saunders et al have pointed out that although heroic 
measures, such as exchange transfusion, cross circula-
tion and isolated liver perfusion, can reverse the 
neurologic and, to an extent, the hematologic complica-
tions of massive liver cell necrosis in some patients, 
none have increased the survival rate (1 5). The same 
unfortunately also applies to newer methods of treatment 
(1). The hope that an «artificial liver» could be developed 
to replace the many intricate functions of the liver, while 
waiting for regeneration to take place, has not been 
borne out in practice because of the complexity of the 
liver itself (2, 7). and because of the surprising finding 
that many of these patients do not regenerate their livers 
adequately, if at all (10, 15). 
In the Cape Town Experience of 119 cases of fulmin-
ant hepatic failure, 68 patients were in grade IV coma. In 
this group the survival rate was only 16% despite inten-
sive care and the use of various additional treatment 
modalities (15, 20). Autopsies were available in 40 pa-
tients. In 23 some regeneration was noted but in only 5 
was this of significant degree. In 7 no regeneration was 
detected at all. Event patients who died late after the 
onset of the illness frequently showed little evidence of 
regeneration (15). This led them to conclude in 1972 that 
-although the liver has an enormous regenerative capaci-
ty in certain experimental situations, and sometimes after 
massive necrosis, this ability has been overemphasized 
in fulminant hepatitis and is not consistent with our ex-
perience in many patients. All the current methods of 
treatment ...... will not influence mortality unless suffi-
cient regeneration occurs spontaneously or can be stimu-
lated therapeutically» (15). This lack of regeneration in 
many patients with severe fulminant hepatic failure has 
been confirmed in other large series (10, 23). The conclu-
sion of a recent conference held at the NIH was that the 
best one can offer a patient with fulminant hepatic failure 
at this time is meticulous intensive care (1, 2). 
If artificial liver support systems are inadequate, and 
lack of regeneration a problem, can anything be done to 
potentiate or stimulate regeneration in patients with ful-
minant hepatic failure? At this time the answer is no, 
largely because of our limited knowledge of what 
switches on or controls liver regeneration. In this editori-
al the authors will address themselves to what is current-
ly known about the control of liver regeneration and 
speculate how this knowledge might be used in the fu-
ture management of patients with fulminant hepatic fail-
ure. 
liver regeneration 
Neither the switch-on nor the switch-off mechanism 
that controls normal liver growth so accurately is known. 
A current area of controversy is whether there are 
specific factors, particularly the so-called portal hepatot-
rophic factors, that potentiate liver regeneration or permit 
it to occur normally once it has commenced, and other 
factors that actually initiate or switch on the regenerative 
response; or alternatively whether both potentiation and 
initiation are caused by the same factor or factors. Recent 
evidence on potentiation of regeneration supports the 
multifactorial concept, particularly with regard to portal 
hepatotrophic factors (14). which has been a consistent 
hypothesis in all work from Denver (19). On the other 
hand, there is no concensus on what actually initiates 
regeneration and whether liver cell growth is controlled 
by stimulators or inhibitors or both. 
The Concept of Potentiation of Regeneration 
This has developed as a result of a better understand-
ing of the role played by the «quality" of blood reaching 
the liver, or the so-called portal hepatotrophic concept. 
which has largely replaced the «flow» or «quantity» of 
blood hypothesis that was widely accepted after 
Bollman's review in 1961 (4). 
Hepatotrophic factors have been studied in vivo using 
a number of ingenious animal models and in vitro using 
liver cell culture systems. It has been clearly de-
monstrated that portal blood specifically influences both 
the morphology and function of the liver on the one 
hand, and liver regeneration on the other (19). These two 
effects will be considered separately although they might 
both be important in the context of liver regeneration 
after liver cell injury. Most of the in vivo data has been 
accumulated from studies in which all or part of the liver 
has been deprived of portal venous return, or in which 
partial or complete removal of non-hepatic splanchnic 
viscera has been performed and by infusing hormones or 
other substances into either the systemic or portal ven-
ous system (19). 
When portal blood is deviated from part or the whole 
of the liver by various technical maneuvers including 
complete portacaval shunting, a well defined portoprival 
state ensues in the liver. Morphological changes include 
hepatocyte atrophy and electron microscopic abbera-
tions, the most striking and specific of which are deple-
tion and disruption of the rough endoplasmic reticulum 
and reduction in membrane bound ribosomes. These 
changes occur rapidly, being almost complete within 4 
days after portacaval shunt. Functional changes include 
inefficient clearing of ammonia and other substances and 
antilipidemic effects (19). 
The striking organelle alterations make it likely that 
the portoprival state will have other subtle functional ef-
fects that are wide ranging and which might even effect 
the regenerative response. 
Investigations from many laboratories, including De-
nver, have clearly demonstrated that portal factors influ-
ence regeneration and that a portoprival state has an 
adverse effect on regeneration. This work has been re-
viewed in detail recently (19). 
A series of studies have been performed in a variety 
of in vivo experimental models over a number of years in 
Denver. In expressing the results in . practical terms, 
which were applicable to both regeneration and mor-
phological and functional changes, it was concluded that 
the most favorable condition for portal perfusion was 
with splanchnic venous blood which contained normal 
amounts of endogenous insulin. The least favorable con-
dition was perfusion with systemic blood. Intermediate in 
quality was splanchnic venous blood that was deficient in 
endogenous insulin but which was rich in other as yet 
unknown elements (19). A recent study using differential 
evisceration has confirmed that gut factors play an im-
portant role in addition to pancreatic factors. The hepatic 
regenerative response after partial hepatectomy in dogs 
was reduced more by evisceration with preservation of 
the pancreas than by pancreatectomy alone (17). This 
further strengthens the multifactorial hypothesis with 
regard to the hepatotrophic factors' role in potentiating 
regeneration by clearly differentiating pancreatic influ-
ences from those originating in the rest of the intra-ab-
dominal gastrointestinal tract. 
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The Concept of Initiation of Regeneration 
All the evidence presented so far supports the cor). 
cept that portal hepatotrophic factors are important as 
potentiators of liver regeneration. The obvious question 
is whether portal hepatotrophic factors also control re-
generation by initiating the process and switching it off 
once liver mass has been restored. To date the most 
compelling argument favoring this controlling or initiat_ 
ing concept for hepatotrophic factors has been the 
changes shown to occur in the hormonally controlled 
«messenger» components in the liver during regenera-
tion using both in vivo and in vitro models (19). Cyclic 
AMP and adenyl cyclase undergo well ordered biphasic 
changes both prior to the onset of the phenomena used 
to quantitate regeneration (DNA synthesis and mitOSis) 
and during regeneration (9). The authors presently con-
cede that these changes may be coincidental and that 
those manifestations that occur prior to DNA synthesis 
could be merely evidence of an earlier stage of a re-
generative response that has already been initiated by 
some other factor or factors. This hypothesis has at least 
as much support from currently available evidence as the 
alternative hypothesis that portal hepatotrophic factors 
are the initiators of hepatic regeneration. 
An important additional, and by no means contradic-
tory, possibility that something in the liver itself, after 
liver cell damage (or partial hepatectomy), contributes to, 
or even initiates, its own regrowth merits careful evalua-
tion. This is not a new concept and the literature, which 
extends back over 50 years, has been reviewed recently 
(19). Although early work was contradictory, various 
groups demonstrated that liver mitoses could be stimu-
lated in intact experimental animals using homologous 
liver mash injected intraperitonatty or intravenously. The 
first truly convinCing evidence of a liver specific mitotic 
stimulator was presented in 1953 (22) and confirmed in 
1957 by Blomqvist in Helsinki (3). He showed that liver 
mash prepared both from weanling (young) rats, and the 
already regenerating remnant of an adult rat liver 48 
hours after partial hepatectomy, showed striking liver 
mitotic stimulatory activity when administered one-time 
intraperitonealty to adult rats. On the other hand, normal 
adult liver mash was not stimulatory. In the meanwhile, 
evidence from both in vivo and in vitro experiments clearly 
demonstrated that animals with regenerating livers con-
tained circulating plasma or serum liver mitotic stimulat-
ory factors (19). Fisher and co-workers, using cross circu-
lation in rats in 1971, not only showed that partial 
hepatectomy in one of a pair of cross circulated animals 
stimulated significant DNA synthesis in the cross circu-
lated partner's intact liver, but also that DNA synthesis 
was similarly stimulated in the partner's intact liver after 
total hepatectomy had been performed in the other rat. 
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postulated that the source of the humoral factor 
TheY not in the liver (8). Although this contention was 
tU~lenged by Levi and Zeppa (12), their work was not 
ctl8roducible (13). This confusing and controversial data 
rep f h ., . I b the liver as a source 0 t e mitotic stlmu atory su -
on nce probably influenced the recent major emphasis on 
tt'rtal hepatotrophic factors as initiators of regeneration. 
pO In 1975 La Brecque and Pesch demonstrated a re-
nerative stimulator substance in the supernatant after ~h speed centrifugation of an extract of rat liver mash 
hich was present in very young (weanling) rat livers, 
:'t only appeared after partial hepatectomy in adult liv-
ers. Their assay system was an already regenerating 
.dult rat liver after 35% hepatectomy (11). Thus attention 
was once again directed to a liver source for the humoral 
factors. The authors have pointed out that, if confirmed, 
thiS would strongly support a liver-plasma physiological 
.xis being important in liver regeneration (19). It is in-
teresting that this possibility was not discussed during a 
symposium on hepatotrophic factors held as recently as 
1977 (14). The authors examined the possibility of there 
being a liver based regenerative stimulator factor using a 
previously described portacaval shunt model (16). This 
model permitted extracts of normal and regenerating liv-
ers to be introduced into the left tied off branch of the 
portal vein and tested for regional as well as general 
hepatic effects. Organelle free cytosol extracts from nor-
mal dog livers and from dog livers after 70% hepatec-
tomy, that had been regenerating for 24, 48 and 72 
hours, were infused for 6 hours only into the tied off left 
portal vein 4 to 6 hours after constructing a portacaval 
shunt. This model once again produced unequivocal re-
sults. A liver mitotic stimulatory effect was not present in 
cytosol extracts from normal or 24 hour regenerating liv-
ers but was present in 48 hour liver remnants and be-
came highly significant in the remnants 72 hours after 
partial hepatectomy, at which time it also reversed the 
atrophy usually caused by portacaval shunt in 3 days 
(18). It is presumably no coincidence that both the full 
development of extract potency from the regenerating 
liver remnant, as well as the full response to it in a sec-
ond animal, required 3 days (18). as this is the same time 
that liver regeneration reaches a peak after partial 
hepatectomy in the dog (9). It was concluded that the ac-
tive regenerating liver extracts contained a growth con-
trol factor or factors which were not insulin or glucagon 
(18). The brief exposure to the extract, shortly after con-
structing the portacaval shunt, and the delayed regenera-
tive response is suggestive of a switch-on or initiating 
mechanism. Unanswered questions include whether the 
production of this stimulatory factor is an independent 
nU.ACI.'.I. quality of the partially resected liver which then creates a 
new environment in which the portal hepatotrophic fac-
tors can be effective or whether the liver factor is depen-
dent from the outset on hepatotrophic substances includ-
ing insulin. The next steps will be to isolate and identify 
the active substance(s) in liver extracts and to determine 
organ and species specificity (18). 
Stimulation of regeneration in the treatment of 
fulminant hepatic failure 
The first practical suggestion of a method to stimulate 
regeneration in fulminant hepatic failure was based on 
the hepatotrophic concept by Farivar and co-workers. 
They investigated insulin and glucagon as important 
hepatotrophic substances and showed that they were 
effective in prolonging survival in mice with fulminant 
murine hepatitis (6). They concluded that the possibility 
that insulin and glucagon might also beneficially influ-
ence the clinical course of acute liver cell injury in man 
merited investigation. This conclusion is open to criticism 
in that the histologic picture of murine hepatitis is not the 
same as human fulminant hepatic failure (5). the mean 
survival time was not as prolonged and there were fewer 
survivors (15% versus 40%) when treatment was'de-
layed, DNA labelling, indicative of hepatic regeneration, 
was depressed equally in treated and control mice at 24 
hours, and last but not least patients with fulminant 
hepatic failure have been shown to have raised levels of 
both insulin and glucagon anyway (1). 
The next practical suggestion is to test the mitotic 
stimulatory factor, which has been shown to be present 
in regenerating liver cytosol, in fulminant hepatic failure. 
This has not been proposed previously but will probably 
have to await the isolation and identification of the 
cytosol factor. Ideally, if a purified stimulatory factor can 
be identified, it should first be tested in a suitable animal 
model. Unfortunately, this poses problems as a truly 
suitable animal model of fulminant hepatic failure, meet-
ing all the defined criteria, has not yet been developed 
(21). Nevertheless, the cytosol extract should at least be 
tested in the best available animal model. Because of the 
deficiencies of animal models, the authors believe that a 
negative result should not prevent the extract being 
tested in patients. Initial pilot tests should probably be 
limited to patients with grade IV coma, particularly pa-
tients over 45 years of age. Thereafter, it must be sub-
jected to a properly controlled clinical trial, even accept-
ing the multiple difficulties inherent in conducting clinical 
trials in fulminant hepatic failure (1). 
Conclusion 
Many patients with severe fulminant hepatic failure 
fail to regenerate their liver adequately. Although there 
51 
are no currently available methods of stimulating liver 
regeneration in these patients, the possibility of isolating 
and purifying an active factor from an already regenerat-
ing liver and using this to stimulate or even initiate re-
generation in this setting is an important practical goal. 
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